Nilotinib Eg

Nilotinib, the active ingredient in Nilotinib Eg, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia in adult patients who have the Philadelphia chromosome-positive disease.

GNH USA supplies Nilotinib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy that acts on the BCR‑ABL tyrosine‑kinase pathway in chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): improves hematologic and cytogenetic response in adult patients. - Chronic myeloid leukemia (accelerated phase): helps achieve disease control and delay progression. - Chronic myeloid leukemia (blast phase): used as part of combination regimens to reduce leukemic burden.

Common side effects are generally mild to moderate and may resolve with continued therapy.

Common Side Effects: - Nausea - Diarrhea - Rash or skin irritation - Headache - Fatigue - Muscle pain or cramps

Serious or Rare Side Effects: - QT interval prolongation and cardiac arrhythmias - Arterial occlusive events (e.g., peripheral vascular disease) - Pancreatitis - Severe hepatic injury - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Tumor lysis syndrome

Nilotinib requires careful monitoring and specific precautions to ensure safe use.

- Dose adjustment in hepatic impairment: reduce dose in patients with moderate to severe liver dysfunction. - Monitor cardiac function: obtain baseline ECG and repeat periodically to detect QT prolongation. - Avoid concomitant QT‑prolonging drugs: co‑administration may increase risk of arrhythmia. - Regular blood count monitoring: assess for cytopenias during treatment. - Pregnancy and lactation: safety unknown; avoid use unless benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and heighten adverse‑event risk. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): additive effect on cardiac repolarization. - Antacids containing aluminum or magnesium: can reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure, reducing efficacy. - Warfarin: nilotinib can increase INR; monitor coagulation parameters. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): higher risk of myopathy; consider dose adjustment or alternative lipid‑lowering therapy.